big future!!!!

I thought it bounced of 3.6 yesterday well its an uptrend if it closes above 4 today or tomorrow.There has been some big buy orders of late and they did get a speeding ticket.Drug trial are suppose to start early 2005.Its earnings per share is 1.4 and its PE is 2.9

DERMAPORTATION – electro-inductive lipid aggregation as a means of managing dermal permeability.
Benson H, Quirk C, Snowden J, Eijkenboom M and Edwards J


ABSTRACT:
Dermaportation is a new transdermal drug delivery platform technology that increases skin permeability. It can be used to assist in the transdermal delivery of a range of therapeutic compounds thereby improving effectiveness of currently available topical treatments and creating new transdermal delivery opportunities.

Unlike electroporation, sonophoresis and other lipid disruptive processes that use high energy charges to break-up the lipid structure, Dermaportation uses low energy fields. This is likely to encourage localised lipid aggregation while retaining the basic integrity of the bilayer structure.

Dermaportation energy characteristics can be programmed thereby providing the potential to control the rate of drug delivery, the sequence of drug passage and the closure of voids when required.

No other known technique provides this level of control.


INTRODUCTION
Transdermal drug delivery is an active area of medical and dermatological research. While the convenience, safety and benefits of through-the-skin administration are well understood, the delivery of all but a few simple compounds via the topical route has proven difficult, unreliable or excessively slow. This is due to the largely impermeable nature of the outermost layer of the skin, the stratum corneum. This top-most layer, usually just 15 micrometers in thickness, is responsible for approximately 90% of the skins barrier effect.

STRATUM CORNEUM BILAYERS
The barrier effect of the stratum corneum is the result of the intercellular lipid matrix which is composed of long chain ceramides, free fatty acids, cholesterol and other lipids. The lipids are arranged into bilayers with their hydrocarbon chains aligned to form the oily bilayer core, while their electrically charged or polar head groups face outwards in the aqueous environment. These domains confer a highly selective filter-like structure between the flattened corneocytes in the upper most layer of the skin. In contrast to phospholipid bilayer membranes found elsewhere in the body, the composition of the stratum corneum lipid bilayers is a much more rigid and ordered structure. Consequently the barrier to drug penetration of the skin is much greater compared to other body membranes.

LIPID BILAYER DISRUPTION
The traditional approach to modifying the skin’s structural permeability is to disrupt the lipid bilayer responsible for the skin’s barrier effect.

Disruption can be accomplished using a number of techniques, including sonophoresis or electroporation, which both rely on introducing sufficient energy to breakup the bilayer’s inherent structure. This disrupts the bilayer’s hydrophilic – hydrophobic orientation, creating regions of disorder and random orientation through which some compounds may be introduced.

In the case of electroporation, the energy levels required to achieve this level of break-down can be as high as 900 volts. Given sufficient time, the lipids are believed to self-assemble and repair the damage to the bilayer.

Disruption of this type is a binary process as the required breach is either formed or not.

LIPID AGGREGATION
The Dermaportation technique uses highly controlled patterns of low voltage energy. Rather than destroying the bilayer’s underlying structure, it is proposed that Dermaportation creates temporary constrainments within the lipid bilayers. While the precise methods used to achieve this are a matter of commercial confidentiality, this allows Dermaportation to create temporary regions of low probability densities, which manifest as ring-like voids surrounding a compacted lipid core, through which therapeutic drugs and compounds can readily pass.

The Dermaportation technique is an analogue process where the size, sequence and duration of the generated voids are all controllable.

INDUCING THE DERMAPORTATION EFFECT
The Dermaportation process uses an induction technique as the mechanism for manipulating the stratum corneum lipid bilayers. This technique has a number of important practical and clinical benefits.

TARGETING
The inductive technique used allows Dermaportation to target accurately within 3 dimensions with no need for sophisticated targeting systems. The physical location of the inductive head in relation to the skin allows accurate and defined areas of action while frequency control allows Dermaportation to target the stratum corneum bilayers only, with little or no detectable effect in surrounding tissues.

CONTROL
Dermaportation provides a number of control functions, including void creation, void closure, induced compound mobilisation and controlled release. This allows Dermaportation to be used as a drug delivery protocol rather than a single process.

LOW ENERGY
The amount of energy produced by the Dermaportation system is approximately 1,000 times smaller than the stratum corneum lipid disruptive processes current used. This makes Dermaportation ideally suited to portability, out-patient and homecare usage.

NON-CONTACT
Dermaportation can operate through most non-conductive materials, including bandages, pads and cloths and functions without the requirement for physical contact. This avoids the traditional problems of allergies and burns often associated with contact pads.

PAINLESS
Dermaportation operates using a modality for which humans have no receptors. As a result, the effect is not detectible by the human body and is totally pain free and comfortable to use.

REGULATORY
Inductive processes have been used clinically throughout the world for over 40 years and are currently approved for human use in all major markets, including USA and Europe. The FDA approved the first inductive system in 1979.

CONCLUSION
Dermaportation is a new Transdermal Drug Delivery (TDD) technology that provides an unprecedented level of dermal permeability control. It uses low energy and is ideally suited to clinical, homecare and cosmetic applications. It is a low cost and simple to use technology with a substantial clinical safety record over 40 years, yet provides a new level of control over dermal permeability.

Have a look at there website www.obj.com.au

or have a look at this site about Transdermal
http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=143

this good be big